Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02862522 · ClinicalTrials.gov registry record
Uric Acid Levels and Endothelial Functions
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 229
- Enrollment target
NCT02862522: Completed study, sponsored by Mayo Clinic.
NCT02862522 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 229 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02862522 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 229 participants
- Enrollment target
Study Summary
Uric acid is a risk factor for coronary artery disease (CED) in postmenopausal women but the association with inflammation and coronary microvascular endothelial dysfunction is not well-defined. The aim of this study was to determine the relationship of serum uric acid, inflammatory markers and CED.
Interventions
- OTHER Questionnaire of overall health
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 1992-01 |
| Est. Completion | 2016-02 |
What the finished NCT02862522 record still lists
NCT02862522 is an observational study that tracks outcomes without assigning an intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Questionnaire of overall health is the first listed.
NCT02862522 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02862522 about?
NCT02862522 is a clinical study titled "Uric Acid Levels and Endothelial Functions". Uric acid is a risk factor for coronary artery disease (CED) in postmenopausal women but the association with inflammation and coronary microvascular endothelial dysfunction is not well-defined. The aim of this study was to determine the relationship of serum uric acid, inflammatory markers and CED.
What is the current status of trial NCT02862522?
This trial is currently completed. The enrollment target is 229 participants. The study started on 1992-01. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02862522?
The interventions under investigation include: Questionnaire of overall health (OTHER).
Who is sponsoring clinical trial NCT02862522?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia